Over the past 18 months, the Dual Cure Resin Cement industry trends have been reshaped by a wave of consolidation and innovation. 3M closed its $1.3 bn acquisition of **M*Modal’s dental CAD/CAM division, instantly widening its end-to-end cement workflow, while Kulzer and DentSply Sirona formed a co-branding alliance to bundle universal adhesives with next-generation dual-cure cements across EU clinics, accelerating share in the value segment. Product launches have pivoted toward bioactivity: VOCO’s new ReaLithium dual-cure resin cement incorporates lithium-silicate nano-fillers that cut polymerization shrinkage to <1 %, addressing clinician demands for stronger indirect bonds. Meanwhile, FDA’s 2024 re-classification of self-adhesive resin cements to Class II with special controls is nudging manufacturers toward more rigorous biocompatibility data, raising entry barriers for smaller players. Venture funding has concentrated on Asian chair-side solutions, with Zhengbiao Dental securing US $28 m Series B** to scale 3D-printed dual-cure cement discs tailored for millennial dentists in China. Collectively, these moves signal a market shifting from commoditized SKUs toward technology-enabled, regulated ecosystems.
